Adjunctive treatment with risperidone in clozapine-resistant schizophrenia: A case report and review

Clinical Neuropharmacology

Volumn 30, Issue 2, 2007, Pages 114-121

  Lerma Carrillo, Iván ^a   Molina, Juan D ^a   Cuevas Durán, Teresa ^b   González Parra, Silvia ^a   Blasco Fontecilla, Hilario ^a   Andrade Rosa, Cristina ^b   López Muñoz, Francisco ^c   Alamo, Cecilio ^c  

^a Hospital Dr Rodríguez Lafora   (Spain)

^b HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^c UNIVERSITY OF ALCALÁ   (Spain)

Author keywords

Augmentation; Clozapine; Combination treatment; Resistant schizophrenia; Risperidone

Indexed keywords

CLOZAPINE; HALOPERIDOL; LITHIUM; OLANZAPINE; RISPERIDONE; TRIFLUOPERAZINE; VALPROIC ACID;

ADD ON THERAPY; ADJUVANT THERAPY; ADULT; ANAMNESIS; CASE REPORT; CLINICAL FEATURE; CONVULSION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG DOSE INCREASE; DRUG TREATMENT FAILURE; HUMAN; MALE; MONOTHERAPY; NEUROPHYSIOLOGY; PARANOID SCHIZOPHRENIA; PRIORITY JOURNAL; REVIEW; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; ANTIPSYCHOTIC AGENTS; CLOZAPINE; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; HUMANS; LONGITUDINAL STUDIES; MALE; PSYCHIATRIC STATUS RATING SCALES; REVIEW LITERATURE; RISPERIDONE; SCHIZOPHRENIA;

EID: 34147214251     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.wnf.0000240947.51994.96     Document Type: Review

References (36)

1. Freedman R. Schizophrenia. N Engl J Med 2003;349:1738-1749.
2. Kane JM, Lieberman J. Maintenance pharmacotherapy in schizophrenia. In: Meltzer HY, ed. Psychopharmacology, the Third Generation of Progress: The Emergence of Molecular Biology and Biological Psychiatry. New York, NY: Raven Press, 1987:1103-1109.
3. Kane J, Honigfeld G, Singer J, et al. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988;45:789-796.
4. Brenner HD, Dencker SJ, Goldstein MJ, et al. Defining treatment refractoriness in schizophrenia. Schizophr Bull 1990;16:551-561.
5. Meltzer HY. Defining treatment refractoriness in schizophrenia. Schizophr Bull 1990;16:563-565.
6. Povlsen UJ, Noring U, Fog R, et al. Tolerability and therapeutic effect of clozapine. Acta Psychiatr Scand 1985;71:176-185.
7. Barnes TRE, McEvedy CJB, Nelson HE. Management of treatment resistant schizophrenia unresponsive to clozapine. Br J Psychiatry 1996;169(suppl 31):31-40.
8. Yuzda MSK. Combination antipsychotics: what is the evidence? J Inform Pharmacother 2000;2:300-305.
9. Naber D, Holtzbach R, Perro C, et al. Clinical management of clozapine patients in relation to efficacy and side-effects. Br J Psychiatry 1992;160(suppl 17):54-59.
10. Peacock L, Gerlach J. Clozapine treatment in Denmark: concomitant psychotropic medication and hematologic monitoring in a system with liberal usage policies. J Clin Psychiatry 1994;55:44-49.
11. Stahl SM. Selecting an atypical antipsychotic by combining clinical experience with guidelines from clinical trials. J Clin Psychiatry 1999;60:31-41.
12. Kontaxakis VP, Ferentinos PP, Havaki-Kontaxaki BJ, et al. Cases studies of adjunctive agents in clozapine-resistant schizophrenic patients. Clin Neuropharmacol 2005;28:50-53.
13. Pollack S, Lieberman JA, Fleischacker WW, et al. A comparison of European and American dosing regimens of schizophrenic patients on clozapine: efficacy and side effects. Psychopharmacol Bull 1995;31:315-320.
14. Potter WZ, Ko GN, Zhang LD, et al. Clozapine in China: a review and preview of US/PRC collaboration. Psychopharmacology 1989;99(suppl):S87- S91.
15. Shiloh R, Zemishlany Z, Aizenberg D, et al. Sulpiride augmentation in people with schizophrenia partially responsive to clozapine a double-blind placebo-controlled study. Br J Psychiatry 1997;171:569-573.
16. Mowerman S, Siris SG. Adjunctive loxapine in a clozapine-resistant cohort of schizophrenic patients. Ann Clin Psychiatry 1996;8:193-197.
17. Friedman J, Ault K, Powchik P. Pimozide augmentation for the treatment of schizophrenic patients who are partial responders to clozapine. Biol Psychiatry 1997;42:522-523.
18. Gupta S, Sonnenberg SJ, Frank B. Olanzapine augmentation of clozapine. Ann Clin Psychiatry 1998;10:113-115.
19. Tyson SC, Devane CL, Risch SC. Pharmacokinetic interaction between risperidone and clozapine. Am J Psychiatry 1995;152:1401-1402.
20. McCarthy RH, Terkelsen KG. Risperidone augmentation of clozapine. Pharmacopsychiatry 1995;28:61-63.
21. Morera AL, Barreiro P, Cano-Muñoz JL. Risperidone and clozapine combination for treatment of refractory schizophrenia. Acta Psychiatr Scand 1999;99:305-307.
22. Raskin S, Katz G, Zislin Z, et al. Clozapine and risperidone: combination/augmentation treatment of refractory schizophrenia: a preliminary observation. Acta Psychiatr Scand 2000;101:334-336.
23. Adesanya A, Pantelis C. Adjunctive risperidone treatment in patients with "clozapine-resistant schizophrenia". Aust N Z J Psychiatry 2000;34:533-534.
24. Raju GVL, Ramesh Kumar R, Khanna S. Clozapine-risperidone combination in treatment-resistant schizophrenia. Aust N Z J Psychiatry 2001;35:543.
25. Koreen Ar, Lieberman JA, Kronig M, et al. Cross-tapering clozapine-risperidone combination. Am J Psychiatry 1995;152:1690.
26. Chong SA, Tan CH, Lee HS. Hoarding and clozapine-risperidone combination. Can J Psychiatry 1996;41:315-316.
27. Henderson DC, Goff DC. Risperidone as an adjunct to clozapine therapy in chronic schizophrenics. J Clin Psychiatry 1996;57:395-397.
28. Taylor CG, Flynn SW, Altman S, et al. An open trial of risperidone augmentation of partial response to clozapine. Schizophr Res 2001;48:155-158.
29. De Groot IW, Heck AH, van Harten PN. Addition of risperidone to clozapine therapy in chronically psychotic impatiens. J Clin Psychiatry 2001;62:129-130.
30. Anil Yagcioglu AE, Kivircik Akdede BB, Turgut TI, et al. A double-blind controlled study of adjunctive treatment with risperidone in schizophrenic patients partially responsive to clozapine: efficacy and safety. J Clin Psychiatry 2005;66:63-72.
31. Josiassen RC, Joseph A, Kohegyi E, et al. Clozapine augmented with risperidone in the treatment of schizophrenia: a randomized, double-blind, placebo-controlled trial. Am J Psychiatry 2005;162:130-137.
32. Honer WG, Thornton AE, Chen EYH, et al. Clozapine alone versus clozapine and risperidone with refractory schizophrenia. N Engl J Med 2006;354:472-482.
33. Jackson DM, Ryan C, Evenden J, et al. Preclinical findings with new antipsychotic agents: what makes them atypical? Acta Psychiatr Scand 1994;89(suppl 380):41-48.
34. Kapur S, Zipursky RB, Remington G. Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. Am J Psychiatry 1999;156:286-293.
35. Ereshefsky L. Pharmacologic and pharmacokinetic considerations in choosing an antipsychotic. J Clin Psychiatry 1999;60(suppl 10):20-30.
36. Beauchemin MA, Millaud F, Nguyen KA. A case of neuroleptic malignant syndrome with clozapine and risperidone. Can J Psychiatry 2002;47:886.